Almac Discovery

Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.

Company Type
X Account
@AlmacGroup

Serenatis Bio

Company Profile

Serenatis Bio is a start-up biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness with huge unmet need and commercial opportunity.

Each drug has a different mechanism of action - targeting glutamate, mu-opioid and dopamine receptors - using precision medicine to identify which OCD patients will respond to which drug. 

Sector

Biotech Biotech Subsector Indications
Mental health
Neuroscience Development Phase
Company Type